Given that we identified several SL candidates with roles in T-cell cytotoxicity and the immune response (Additional file 6: Table S5C), identified TUBA1B as a priority class A target in the COAD/READ screen, and showed that MSI can elicit specific vulnerabilities in KMT2DLOF cancer cell lines; we sought to understand the impact of KMT2DLOF on immune markers in MSS and MSI COAD/READ cases and whether KMT2D mutational status might be relevant in the context of ICI treatment. Here, KMT2D is linked to cancer.